Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC).

Balar AV, Iyer G, Al-Ahmadie H, Janakiraman M, Ostrovnaya I, Regazzi AM, Garcia-Grossman IR, Pendse D, Bochner B, Bajorin DF, Milowsky MI, Solit DB.

J Clin Oncol. 2012 Feb 10;30(5_suppl):277. doi: 10.1200/jco.2012.30.5_suppl.277.

PMID:
28143285
2.

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, Bochner BH, Reuter VE, Bajorin DF, Milowsky MI, Taylor BS, Solit DB.

J Clin Oncol. 2013 Sep 1;31(25):3133-40. doi: 10.1200/JCO.2012.46.5740. Epub 2013 Jul 29.

3.

Genome sequencing identifies a basis for everolimus sensitivity.

Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB.

Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23.

4.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A.

Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.

5.

Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, Solit DB.

J Clin Oncol. 2012 Aug 20;30(24):2956-62. doi: 10.1200/JCO.2011.38.2994. Epub 2012 Jun 4.

6.

Genomic complexity and AKT dependence in serous ovarian cancer.

Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She QB, Aghajanian C, King TA, Stanchina Ed, Spriggs DR, Heguy A, Taylor BS, Sander C, Rosen N, Levine DA, Solit DB.

Cancer Discov. 2012 Jan;2(1):56-67. doi: 10.1158/2159-8290.CD-11-0170. Erratum in: Cancer Discov. 2012 Apr;2(4):376. Janikariman, Manickam [corrected to Janakiraman, Manickam].

7.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.

Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.

8.

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.

Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB.

Oncogene. 2012 Jan 26;31(4):446-57. doi: 10.1038/onc.2011.250. Epub 2011 Jul 4.

9.

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.

Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, Heguy A, Tickoo SK, Fine SW, Gopalan A, Chen YB, Balar A, Riches J, Bochner B, Dalbagni G, Bajorin DF, Reuter VE, Milowsky MI, Solit DB.

J Pathol. 2011 Jun;224(2):270-9. doi: 10.1002/path.2892. Epub 2011 May 5.

10.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB.

Cancer Res. 2010 Jul 15;70(14):5901-11. doi: 10.1158/0008-5472.CAN-10-0192. Epub 2010 Jun 22.

11.

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA.

Nat Genet. 2010 Jan;42(1):77-82. doi: 10.1038/ng.491. Epub 2009 Nov 29.

12.

Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management.

Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S, Munjal YP; Concensus Group.

J Assoc Physicians India. 2009 Feb;57:163-70. Review.

PMID:
19582986
13.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA.

Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727.

14.

Genetic predictors of MEK dependence in non-small cell lung cancer.

Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB.

Cancer Res. 2008 Nov 15;68(22):9375-83. doi: 10.1158/0008-5472.CAN-08-2223.

15.

Survival signaling by C-RAF: mitochondrial reactive oxygen species and Ca2+ are critical targets.

Kuznetsov AV, Smigelskaite J, Doblander C, Janakiraman M, Hermann M, Wurm M, Scheidl SF, Sucher R, Deutschmann A, Troppmair J.

Mol Cell Biol. 2008 Apr;28(7):2304-13. doi: 10.1128/MCB.00683-07. Epub 2008 Jan 22.

16.

Etiology and management of ear lobule keloid in South India.

Janakiraman M, Ramakrishnan KM, Jayaraman V, Chandrashekar S, Babu M.

Plast Reconstr Surg. 2007 Jan;119(1):435-7. No abstract available.

PMID:
17255720
17.

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.

Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H.

Cancer Res. 2006 Apr 1;66(7):3401-8.

18.

Stress kinase signaling in cancer: fact or fiction?

Rennefahrt U, Janakiraman M, Ollinger R, Troppmair J.

Cancer Lett. 2005 Jan 10;217(1):1-9. Review.

PMID:
15596290
19.

Regulating cell survival by controlling cellular energy production: novel functions for ancient signaling pathways?

Kuznetsov AV, Janakiraman M, Margreiter R, Troppmair J.

FEBS Lett. 2004 Nov 5;577(1-2):1-4. Review.

20.

Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.

Janakiraman MN, Watenpaugh KD, Tomich PK, Chong KT, Turner SR, Tommasi RA, Thaisrivongs S, Strohbach JW.

Bioorg Med Chem Lett. 1998 May 19;8(10):1237-42.

PMID:
9871742

Supplemental Content

Loading ...
Support Center